Icotrokinra, the first psoriasis pill built as a peptide rather than an injected antibody, now has its first hint that it also quiets the joints of psoriatic arthritis. The hint rests on patients who diagnosed their own arthritis.
A post-hoc pooled analysis published October 18 in the Journal of Psoriasis and Psoriatic Arthritis ↗ gathered 216 people from three Phase 3 skin-psoriasis trials (ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2) who also said they had psoriatic arthritis, a related disease where the same immune misfire that scales the skin also attacks the joints. 149 took icotrokinra once a day, 67 took placebo. At week 16, 47.0 percent of the drug group said their arthritis disease activity had dropped by at least half, against 10.7 percent on placebo. For joint pain, it was 45.5 percent versus 16.1 percent. Put plainly, roughly half the treated patients cleared that halfway bar, and only about one in ten to one in six on placebo did.
The one measure a clinician scored rather than the patient was nails. Psoriatic nail disease is slow and stubborn. On a standard nail-severity index, the icotrokinra group improved 41.6 percent by week 16 while the placebo group got 118.6 percent worse, a split in opposite directions rather than a smaller version of the same move. Side-effect rates were similar in the two groups.
What the drug is
Icotrokinra, sold as Icotyde and co-developed by Johnson & Johnson and Protagonist Therapeutics, is a once-daily tablet that blocks the interleukin-23 receptor, an inflammation switch that drives both psoriasis and psoriatic arthritis. The strongest drugs against that switch are antibodies given by injection. Getting a peptide, a short chain of amino acids the gut is built to digest, to survive the stomach and hold a chronic disease in check is the engineering the whole program is built on. The FDA approved it for plaque psoriasis in March ↗, for patients 12 and up who weigh at least 40 kilograms.
Why this is a signal, not a result
Three things hold the piece back from being proof. The arthritis diagnoses were self-reported, with no rheumatologist confirming them against the usual criteria or imaging, so the 216 are a group who believe they have psoriatic arthritis, not a verified cohort. The joint measures were patient questionnaires, a global activity score and a pain score, not the swollen-and-tender joint counts that anchor arthritis trials. And the p-values are nominal, meaning the analysis was read off trials that were not set up to prove a joint effect. The authors, led by Iain McInnes at Glasgow, say as much.
That is why the nail number carries extra weight here. It is the only outcome a doctor measured instead of the patient, and it is the one that moved in opposite directions between the groups.
What is actually being tested
The real test is already enrolling. Two dedicated trials, ICONIC-PsA 1 and ICONIC-PsA 2, are recruiting people with confirmed active psoriatic arthritis and will score joints the way arthritis trials are supposed to. About a third of psoriasis patients go on to develop the joint form, and for them a pill that treats skin and joints at once would be worth having, because the IL-23 antibodies that already carry a psoriatic-arthritis label, like guselkumab, are injections.
This section covered icotrokinra's two-year skin-clearance data ↗ two weeks ago, where the question was whether a swallowed peptide could hold up on the body's hardest-to-treat sites. This is a different claim about a different disease from the same pill, and a thinner one. peptidemodel tracks oral peptides as a drug class rather than a curiosity, and icotrokinra is the one that keeps generating data on how far a swallowed peptide can reach.